好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Atogepant on the Improvement in the Severity of Overall Migraine Symptoms Using PGI-S: Post hoc Analyses from ADVANCE, ELEVATE, and PROGRESS
Headache
P9 - Poster Session 9 (11:45 AM-12:45 PM)
12-006
To evaluate the proportion of participants treated with atogepant (Ato) versus placebo (Pbo) who had at least moderate symptoms at baseline and had an improvement in severity of overall migraine symptoms at Weeks 4, 8, and 12 in three phase 3 Ato trials.
Ato is an oral, calcitonin gene-related peptide receptor antagonist approved for preventive treatment of migraine in adults. ADVANCE, ELEVATE, and PROGRESS were phase 3, multicenter, randomized, double-blind, Pbo-controlled, 12-week trials that included adults with episodic migraine (EM), EM with prior inadequate responses to 2-4 classes of oral preventive treatments, and chronic migraine (CM), respectively.
This post hoc analysis used the patient global impression–severity (PGI-S) scale to assess the improvement in severity of overall migraine symptoms between Ato 60 mg daily and Pbo groups. All participants experienced at least moderate symptoms at baseline and improvement was quantified by a single item questionnaire with 5-point rating scale ranging from “0-none” to “4-very severe,” with higher scores indicating greater severity. 
Across three Ato trials, a higher proportion of participants treated with Ato achieved no/mild migraine symptoms at Week 4 compared with Pbo [(ADVANCE: Ato, 70.3%(121/172), Pbo, 46.5%(72/155), P<0.001) (ELEVATE: Ato, 62.0%(80/129), Pbo, 38.3%(51/133), P<0.001) (PROGRESS: Ato, 49.3%(108/219), Pbo, 35.5%(76/214), P=0.004)]. Results were consistent at Week 8 for all trials and Week 12 for ADVANCE and ELEVATE. A higher proportion of participants treated with Ato had no/mild overall migraine symptoms across all three timepoints in each trial compared to Pbo [(ADVANCE: Ato, 53.5%(92/172), Pbo, 25.2%(39/155), P<0.001) (ELEVATE: Ato, 38.0%(49/129), Pbo, 17.3%(23/133), P<0.001) (PROGRESS: Ato 32.9%(72/219), Pbo 17.8%(38/214), P<0.001)]. 
A higher proportion of participants achieved no/mild migraine symptoms, as assessed by PGI-S, with Ato treatment compared with Pbo starting at Week 4. A higher proportion of Ato-treatment participants had no/mild migraine symptoms across three timepoints in the three phase 3 trials.
Authors/Disclosures
Belinda A. Savage-Edwards, MD, FAAN (Rehabilitation & Neurological Services)
PRESENTER 		The institution of Dr. Savage-Edwards has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Llly. The institution of Dr. Savage-Edwards has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Easai. The institution of Dr. Savage-Edwards has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilly. The institution of Dr. Savage-Edwards has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Association of Neurology Journal. Dr. Savage-Edwards has or had stock in Eli Lilly.Dr. Savage-Edwards has or had stock in AbbVie. The institution of Dr. Savage-Edwards has received research support from Eli LIlly Co.. The institution of Dr. Savage-Edwards has received research support from AbbVie. The institution of Dr. Savage-Edwards has received research support from IQVIA.
Pranav Gandhi Pranav Gandhi has received personal compensation for serving as an employee of AbbVie. Pranav Gandhi has stock in AbbVie Inc.
Umer Najib, MD, FAAN (West Virginia University Hospitals) Dr. Najib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Najib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck . Dr. Najib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie . The institution of Dr. Najib has received research support from Eli Lilly. The institution of Dr. Najib has received research support from Abbvie.
Hsiangkuo Yuan, MD, PhD (Jefferson Headache Center) An immediate family member of Dr. Yuan has received personal compensation for serving as an employee of Merck. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Yuan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Salvia. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerenovous. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Regional Anesthesia and Pain Medicine. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Headache and Pain Reports. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cephalalgia. The institution of Dr. Yuan has received research support from NIH. The institution of Dr. Yuan has received research support from American Headache Society. The institution of Dr. Yuan has received research support from Pfizer. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Invited speaker with Chinese Stroke Association.
Kandavadivu Umashankar (AbbVie) Kandavadivu Umashankar has received personal compensation for serving as an employee of AbbVie.
Molly Duan (Abbvie) Molly Duan has received personal compensation for serving as an employee of AbbVie.
Jonathan Stokes (AbbVie) Jonathan Stokes has nothing to disclose.
Teshamae Monteith, MD, FAAN (University of Miami) Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for American Headache Society . Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Monteith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cephalalgia. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for New England Journal of Medicine JW. The institution of Dr. Monteith has received research support from AbbVie. The institution of Dr. Monteith has received research support from lilly. The institution of Dr. Monteith has received research support from Ipsen. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a 好色先生 with Medscape. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a 好色先生 with Massachusetts Medical Society . Dr. Monteith has a non-compensated relationship as a President Elect with Florida Society of Neurology that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Editorial Board /Board Member with American Migraine Foundation that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Board Member with International Headache Society that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Pfizer that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Abbvie that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Theranica that is relevant to AAN interests or activities.
Jessica Ailani, MD, FAAN (Medstar Georgetown Neurology) Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspya. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kallyope. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Self Magazine. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. The institution of Dr. Ailani has received research support from Lundbeck. The institution of Dr. Ailani has received research support from Merz. The institution of Dr. Ailani has received research support from Pfizer. Dr. Ailani has received research support from Mi-Helper. The institution of Dr. Ailani has received research support from ShiraTronic. Dr. Ailani has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to AAN interests or activities.